BioSpace News Archive

Pfizer Focuses on Four Main Cancer Types, Eyes Eight Blockbusters by 2030

At Thursday’s Oncology Innovation Day, Pfizer laid out its business strategy which includes building up its biologics business, specifically antibody-drug conjugates and bispecific antibodies.

March 1, 2024
·
2 min read
·
Tristan Manalac
Business

ADC Market Will Remain Hot in Oncology, Reaching $30B by 2028: Report

Antibody-drug conjugates are a breakthrough in targeted cancer therapy and will continue to attract big pharma investment over the next few years, finds a new report from market intelligence firm Evaluate.

March 1, 2024
·
3 min read
·
Tyler Patchen
Drug Development

Ironwood Nabs Phase III Win, Still Sees Stock Nosedive

Despite Ironwood Pharmaceuticals’ apraglutide getting positive late-stage study results in treating short bowel syndrome with intestinal failure, the stock plummeted nearly 40% on Thursday.

March 1, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Palatin’s Dry Eye Drug Candidate Flops in Phase III Trial

Palatin Technologies’ melanocortin agonist PL9643 came up short in a late-stage study evaluating its safety and efficacy.

March 1, 2024
·
2 min read
·
Tyler Patchen
Business

Rare Disease Day Reminds Biopharma of Opportunities, Challenges

The annual observance highlights how far the industry has come and serves as a wake-up call for how far it must still go to meet the needs of patients with rare diseases.

March 1, 2024
·
3 min read
·
Greg Slabodkin
Drug Development

FogPharma Raises $145M in Series E Financing, Targets Solid Tumors

FogPharma’s latest financing round will help fund the ongoing clinical development of the company’s potential first-in-class intracellular TCF-blocking β-catenin inhibitor being evaluated in a Phase I/II study.

March 1, 2024
·
2 min read
·
Tyler Patchen
Policy

AstraZeneca Loss in Court Not a Surprise, in Line with Other IRA Lawsuits

A federal court in Delaware ruled Friday that the pharma company had no “entitlement” to any price above what the buyer is willing to pay.

March 1, 2024
·
2 min read
·
Neil Versel
Policy

RSV Shots May Slightly Raise Risk of Rare Autoimmune Disorder in Older Adults

The FDA and CDC warned Thursday of a small increased risk of developing Guillain-Barré syndrome in older adults after immunization with respiratory syncytial virus vaccines from GSK and Pfizer.

March 1, 2024
·
2 min read
·
Tristan Manalac
Business

Gilead Secures $210M from VC to Build Trodelvy’s Clinical Case in NSCLC

Retaining the full rights to Trodelvy, Gilead now has access to $210 million in financing from venture capital firm Abingworth to help push the antibody-drug conjugate into non-small cell lung cancer studies.

March 1, 2024
·
2 min read
·
Tristan Manalac
Business

Kenai Emerges from Stealth With $82M Series A, Targets Parkinson’s

Formerly known as Ryne Bio, Kenai Therapeutics emerged on Thursday with backing from several groups and has a cell therapy candidate going after Parkinson’s disease.

March 1, 2024
·
2 min read
·
Tyler Patchen